Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Scott

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 8, 2023
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infectionAnna C Nilsson, John Pullman, Piotr Napora, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyPaul Kwo, Norman Gitlin, Ronald Nahass, et al.
Cardiology in the Young|November 22, 2024
Elevating diversity, inclusion, and health equity in Pediatric Heart Network Scholars grant funding: unique opportunities and lessons learnedMichelle C Wallace, L LuAnn Minich, Lara S Shekerdemian, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Gastroenterology and Hepatology|January 19, 2016
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South KoreaLai Wei, Tao Han, Dongliang Yang, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
Asia-Pacific Journal of Public Health|June 2, 2020
Guidelines for Complementary Feeding of Infants in the Asia Pacific Region: APACPH Public Health Nutrition GroupColin Binns, Mi Kyung Lee, Wah Yun Low, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 8, 2023
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infectionAnna C Nilsson, John Pullman, Piotr Napora, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyPaul Kwo, Norman Gitlin, Ronald Nahass, et al.
Cardiology in the Young|November 22, 2024
Elevating diversity, inclusion, and health equity in Pediatric Heart Network Scholars grant funding: unique opportunities and lessons learnedMichelle C Wallace, L LuAnn Minich, Lara S Shekerdemian, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Gastroenterology and Hepatology|January 19, 2016
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South KoreaLai Wei, Tao Han, Dongliang Yang, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
Asia-Pacific Journal of Public Health|June 2, 2020
Guidelines for Complementary Feeding of Infants in the Asia Pacific Region: APACPH Public Health Nutrition GroupColin Binns, Mi Kyung Lee, Wah Yun Low, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Pageof 8